SCHEMBL16635790

SCHEMBL16635790

O=C(O)C1CCCCC1c1coc(-c2ccc(F)cc2)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.49
HDAC1 Q13547 1/20 0.44
HDAC8 Q9BY41 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
LMNA P02545 2/20 0.41
USP7 Q93009 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
GAA P10253 1/20 0.39
TSHR P16473 1/20 0.39
KMT2A Q03164 1/20 0.39
PDE4B Q07343 2/20 0.39
TAAR1 Q96RJ0 1/20 0.38
TBXA2R P21731 1/20 0.37
APAF1 O14727 1/20 0.36
POLB P06746 1/20 0.36
GRK2 P25098 1/20 0.36
APOBEC3G Q9HC16 1/20 0.36
HTT P42858 1/20 0.36
SCN9A Q15858 1/20 0.36
RAB9A P51151 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16636340 0.86 HPGD (0.48) HPGDHDAC1HDAC8HDAC6LMNA
SCHEMBL16636338 0.86 HPGD (0.48) HPGDHDAC1HDAC8HDAC6LMNA
SCHEMBL16635861 0.76 SMN1; SMN2 (0.38) HPGDHDAC1HDAC8HDAC6SMN1; SMN2
SCHEMBL16635958 0.75 LMNA (0.50) LMNASMN1; SMN2GAAKMT2ATAAR1
SCHEMBL16618101 0.72 CTSK (0.49) HPGDSMN1; SMN2GAAKMT2ATAAR1
SCHEMBL14921525 0.72 SMN1; SMN2 (0.51) SMN1; SMN2KMT2ATAAR1TBXA2RHTT
SCHEMBL14921526 0.72 SMN1; SMN2 (0.51) SMN1; SMN2KMT2ATAAR1TBXA2RHTT
SCHEMBL14921524 0.72 SMN1; SMN2 (0.51) SMN1; SMN2KMT2ATAAR1TBXA2RHTT
SCHEMBL3648971 0.69 SMN1; SMN2 (0.48) SMN1; SMN2TAAR1TBXA2RHTT
SCHEMBL31604689 0.68 HPGD (0.65) HPGDHDAC1HDAC8HDAC6GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3054947-B1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME (US) 2021-11-17 EP disclosed
US-9573913-B2 Cathepsin cysteine protease inhibitors MERCK SHARP & DOHME CORP. (US) 2017-02-21 US disclosed
US-20160244417-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-08-25 US disclosed
EP-3054947-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2016-08-17 EP disclosed
WO-2015051479-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-04-16 WO disclosed
WO-2015054038-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160244417-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS CTSB, CTSS, CTSZ HPGD 3020/4885HDAC1 650/4885HDAC8 910/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.